Hologic (NASDAQ:HOLX) PT Raised to $95.00 at JPMorgan Chase & Co.

Hologic (NASDAQ:HOLX) had its price objective boosted by JPMorgan Chase & Co. from $91.00 to $95.00 in a research report report published on Tuesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the medical equipment provider’s stock.

Several other equities analysts have also commented on the company. StockNews.com upgraded Hologic from a hold rating to a buy rating in a research note on Friday, May 3rd. Argus lifted their target price on Hologic from $89.00 to $95.00 and gave the company a buy rating in a research note on Thursday, May 9th. Citigroup upgraded Hologic from a neutral rating to a buy rating and lifted their target price for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Stephens assumed coverage on Hologic in a research note on Thursday, June 27th. They issued an overweight rating and a $87.00 target price on the stock. Finally, Royal Bank of Canada lifted their target price on Hologic from $81.00 to $82.00 and gave the company a sector perform rating in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of $87.60.

Hologic Stock Up 0.5 %

NASDAQ:HOLX opened at $83.64 on Tuesday. Hologic has a twelve month low of $64.02 and a twelve month high of $84.15. The company has a market cap of $19.43 billion, a price-to-earnings ratio of 42.67, a price-to-earnings-growth ratio of 2.59 and a beta of 0.99. The stock has a fifty day simple moving average of $75.33 and a 200-day simple moving average of $75.32. The company has a current ratio of 3.99, a quick ratio of 3.29 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period last year, the company earned $0.93 earnings per share. Analysts anticipate that Hologic will post 4.08 EPS for the current year.

Insiders Place Their Bets

In related news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the completion of the sale, the director now owns 45,472 shares of the company’s stock, valued at $3,615,024. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at $92,755,443.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the sale, the director now directly owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The disclosure for this sale can be found here. Corporate insiders own 1.75% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of HOLX. Innealta Capital LLC acquired a new position in Hologic in the second quarter valued at approximately $25,000. iA Global Asset Management Inc. acquired a new position in Hologic in the first quarter valued at approximately $37,000. Allworth Financial LP lifted its holdings in Hologic by 39.3% in the fourth quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 179 shares during the period. Mather Group LLC. acquired a new position in Hologic in the first quarter valued at approximately $48,000. Finally, Massmutual Trust Co. FSB ADV lifted its holdings in Hologic by 24.7% in the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after acquiring an additional 137 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.